Has Palivizumab prophylaxis effect on long time protection cystic fibrosis children from infections?
A. Folino (Torino, Italy), M. Fissore (Novara, Italy), I. Stura (Torino, Italy), F. Del Monte (Torino, Italy), I. Castagno (Novara, Italy), I. Esposito (Torino, Italy), E. Bignamini (Torino, Italy)
Source: International Congress 2019 – Infection and inflammation in cystic fibrosis
Session: Infection and inflammation in cystic fibrosis
Session type: Thematic Poster
Number: 982
Disease area: Paediatric lung diseases, Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Folino (Torino, Italy), M. Fissore (Novara, Italy), I. Stura (Torino, Italy), F. Del Monte (Torino, Italy), I. Castagno (Novara, Italy), I. Esposito (Torino, Italy), E. Bignamini (Torino, Italy). Has Palivizumab prophylaxis effect on long time protection cystic fibrosis children from infections?. 982
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Viral infections trigger exacerbations of cystic fibrosis in adults and children Source: Eur Respir J 2012; 40: 510-512 Year: 2012
Palivizumab prophylaxis for respiratory syncytial virus (RSV) in infants with cystic fibrosis (CF) and respiratory illness hospitalizations Source: International Congress 2015 – Paediatric pulmonary infections Year: 2015
Palivizumab: Is it cost effective to extend the vaccination period for patients at risk of severe respiratory syncytial virus infection? Source: Virtual Congress 2021 – Acute and chronic lung infections in children Year: 2021
The efficacy of early eradication therapy in prevention of chronic pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 486s Year: 2006
LATE-BREAKING ABSTRACT: Is there a relationship between use of inhaled antibiotics and prevalence of fungal isolates in the respiratory secretions of people with cystic fibrosis? A retrospective data analysis Source: International Congress 2015 – Cystic fibrosis: assessment and treatment Year: 2015
The effect of palivizumab prophylaxis on serious early childhood wheezing Source: Annual Congress 2009 - Diagnosis and treatment of viral respiratory infections in early childhood Year: 2009
Usefulness of long term treatment with azithromycin in patients with bronchiectasis (non cystic fibrosis) Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Survey of microbiology, pseudomonas eradication and antimicrobial prophylaxis in adult patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011
Emerging role of difficult microrganisms in respiratory tract infections of patients with cystic fibrosis with or without lung transplantation Source: Eur Respir J 2003; 22: Suppl. 45, 514s Year: 2003
Emerging pathogens in cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66 Year: 2006
Longitudinal monitoring of sinonasal and oral bacterial reservoirs to prevent chronic lung infection in people with cystic fibrosis Source: ERJ Open Res, 6 (3) 00115-2020; 10.1183/23120541.00115-2020 Year: 2020
The role of inhaled antibiotics in bronchial infection Source: Eur Respir Monogr 2013; 60: 120-126 Year: 2013
Audit of management of pseudomonas aeruginosa infection in children with cystic fibrosis Source: Annual Congress 2009 - Cystic fibrosis: advances in clinical research Year: 2009
Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe Source: ERJ Open Res, 7 (4) 00411-2021; 10.1183/23120541.00411-2021 Year: 2021
Efficacy of two different vaccination schemes for influenza annual vaccination in cystic fibrosis patients 3-8-years-old Source: Eur Respir J 2001; 18: Suppl. 33, 539s Year: 2001
Is it effective to administer corticosteroids late for neonatal chronic lung disease? Source: Eur Respir J 2004; 24: Suppl. 48, 620s Year: 2004
Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014
Effect of zinc supplementation on respiratory infections in children with cystic fibrosis Source: Annual Congress 2009 - Host factors in paediatric bacterial respiratory infection Year: 2009